A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the maximum safe dose of the true human monoclonal antibody, 514G3,
in the treatment of patients with Staphylococcus Aureus bacteremia. Preliminary evidence of
efficacy will be evaluated as well. Patients will receive 514G3 plus antibiotics or placebo
plus antibiotics in approximately a 3 to 1 ratio.